Literature DB >> 10344723

Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation.

J D Wang1, S Takahara, N Nonomura, N Ichimaru, K Toki, H Azuma, K Matsumiya, A Okuyama, S Suzuki.   

Abstract

BACKGROUND: We previously reported that FTY720, a metabolite from Isaria sinclairii, induced some cancer cells to undergo apoptosis, and that FTY720-induced apoptosis was not related to Fas-antigens. In this study we investigated whether FTY720 was able to induce apoptosis in an androgen-independent prostate cancer cell line, DU145, which is not only resistant to androgen-withdrawal-induced apoptosis but also Fas- and TNF-alpha-mediated apoptosis.
METHODS: Cell survival and morphological change were examined and apoptosis was confirmed by DNA isolation and analysis of DNA fragmentation. Caspase activation was studied by using anti-caspase-1 and anti-caspase-3 antibodies. To determine whether caspase activation is central to FTY720-induced apoptosis, caspase inhibitor was added to the media 24 hr prior to the addition of FTY720.
RESULTS: We found that FTY720 rapidly induced apoptosis in DU145 cells, and that caspase-3 was activated during FTY720-induced apoptosis. In contrast, normal human prostate stromal cells were resistant to FTY720. Furthermore, FTY720-induced apoptosis was prevented by caspase-3 inhibitor.
CONCLUSIONS: The data in this report show that FTY720 is a potential strong antitumor agent for cell line DU145, and provide the first evidence for involvement of caspase-3 in apoptosis of an androgen-independent prostate cancer cell line. Activation of such caspases may provide a means for eliminating androgen-independent prostate cancer in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10344723     DOI: 10.1002/(sici)1097-0045(19990615)40:1<50::aid-pros6>3.0.co;2-n

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  27 in total

1.  Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.

Authors:  Takashi Yoshino; Hiroko Tabunoki; Shigeo Sugiyama; Keitaro Ishii; Seung U Kim; Jun-Ichi Satoh
Journal:  Cell Mol Neurobiol       Date:  2011-04-26       Impact factor: 5.046

2.  Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.

Authors:  Giulia Marvaso; Agnese Barone; Nicola Amodio; Lavinia Raimondi; Valter Agosti; Emanuela Altomare; Valerio Scotti; Angela Lombardi; Roberto Bianco; Cataldo Bianco; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2014-03-21       Impact factor: 4.742

Review 3.  Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.

Authors:  Christina Voelkel-Johnson; James S Norris; Shai White-Gilbertson
Journal:  Adv Cancer Res       Date:  2018-06-20       Impact factor: 6.242

4.  Induction of lymphocyte apoptosis in rat liver allograft with ongoing rejection by FTY720.

Authors:  X K Li; A Tamura; M Fujino; L Guo; T Kakefuda; N Funeshima; S Enosawa; M Amari; S Naoe; H Amemiya; S Suzuki
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

5.  Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod).

Authors:  Salma Buddaseth; Wiebke Göttmann; Rainer Blasczyk; Trevor Huyton
Journal:  Cancer Biol Ther       Date:  2013-12-12       Impact factor: 4.742

Review 6.  Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.

Authors:  Dmitri Pchejetski; Torsten Böhler; Justin Stebbing; Jonathan Waxman
Journal:  Nat Rev Urol       Date:  2011-09-13       Impact factor: 14.432

7.  The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas.

Authors:  Karl Quint; Norbert Stiel; Daniel Neureiter; Hans Ulrich Schlicker; Christopher Nimsky; Matthias Ocker; Herwig Strik; Malgorzata Anna Kolodziej
Journal:  Tumour Biol       Date:  2014-06-06

8.  Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720.

Authors:  Natália R Salinas; Camila T Lopes; Patrícia V Palma; Celina T Oshima; Valquiria Bueno
Journal:  Pathol Oncol Res       Date:  2009-02-12       Impact factor: 3.201

9.  Altered expression of signaling genes in Jurkat cells upon FTY720 induced apoptosis.

Authors:  Fang Wang; Wenfeng Tan; Dunming Guo; Xiaomin Zhu; Keqing Qian; Shaoheng He
Journal:  Int J Mol Sci       Date:  2010-09-02       Impact factor: 5.923

10.  FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.

Authors:  Francesca Tonelli; Keng Gat Lim; Carolyn Loveridge; Jaclyn Long; Stuart M Pitson; Gabor Tigyi; Robert Bittman; Susan Pyne; Nigel J Pyne
Journal:  Cell Signal       Date:  2010-06-04       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.